Navigation Links
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
Date:7/25/2014

utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.

 GALMED PHARMACEUTICALS LTD.Condensed Consolidated Balance SheetsU.S. Dollars in thousands, except share data and per share dataSuccessorPredecessorAs of
June 30, 2014As of
December 31,
2013UnauditedAuditedAssetsCurrent AssetsCash and cash equivalents$
37,399

$
37
Other accounts receivable61

16Total current assets37,640

153Property and equipment, net24

13Total assets$
37,484'/>"/>

SOURCE Galmed Pharmaceuticals Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 Increasing its efforts to ... launches its first three episodes of The GMO TRUTH podcast ... this month, as it continues its mission to discover the ... project's first phase, to “uncover the truth about the GMOs ... , The GMO Truth Podcast is an expansion of the ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... financial results for the quarter,ended March 31, 2008., ... net revenue of,$372.2 million compared to net revenue of ... increase was primarily due to increased,product and service revenue ...
... dynamic stabilization,nonfusion segments skyrocketed, according to Millennium Research Group,s US ... ... Millennium Research Group,s,(MRG) US Spine Marketrack(TM) results indicate that ... and surgeon,awareness and new product releases starting in Q3 2007 ...
... will be enrolled to evaluate R7128 1500mg BID in HCV,genotypes 2 and 3 prior ... ... 1:00 PM ET (US) ... CEST (Milan) --, PRINCETON, N.J. and MILAN, Italy, April 24 ,Pharmasset, Inc. (Nasdaq: ...
Cached Biology Technology:Inverness Medical Innovations Announces First Quarter 2008 Results 2Inverness Medical Innovations Announces First Quarter 2008 Results 3Inverness Medical Innovations Announces First Quarter 2008 Results 4Inverness Medical Innovations Announces First Quarter 2008 Results 5Inverness Medical Innovations Announces First Quarter 2008 Results 6Inverness Medical Innovations Announces First Quarter 2008 Results 7Inverness Medical Innovations Announces First Quarter 2008 Results 8Inverness Medical Innovations Announces First Quarter 2008 Results 9Inverness Medical Innovations Announces First Quarter 2008 Results 10Adoption of Spinal Nonfusion Technologies Doubled in One Year 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 3Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 4Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 5
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... standing member of the IOF Board and leading researcher ... the recipient of the prestigious Pierre Delmas Award. The ... Osteoporosis & Osteoarthritis (ESCEO13-IOF), currently being held in Rome, ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ...
... the University of Alberta are abuzz after using fruit ... caffeine,s lethal effects on cancer cellsresults that could one ... Previous research has established that caffeine interferes with ... finding that has generated interest in using the stimulant ...
... past, now has had its genome sequenced, providing a ... the adaptation from an aquatic environment to land. A ... Director of Molecular Genetics at the Benaroya Research Institute ... the University of Washington, will publish "The African coelacanth ...
Cached Biology News:Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... Total Canine Endostatin. Canine Cytokine ... products include a line of enzyme-linked ... reagents used for multiple research applications. ... are ultra-sensitive, quick and dependable assays. ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: